On Friday, Immunovant Inc (NASDAQ: IMVT) opened higher 3.60% from the last session, before settling in for the closing price of $17.5. Price fluctuations for IMVT have ranged from $12.72 to $34.47 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -12.18% over the past five years. Company’s average yearly earnings per share was noted -4.63% at the time writing. With a float of $68.63 million, this company’s outstanding shares have now reached $170.11 million.
Let’s look at the performance matrix of the company that is accounted for 362 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is -258093.12%.
Immunovant Inc (IMVT) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Immunovant Inc is 59.89%, while institutional ownership is 55.50%. The most recent insider transaction that took place on Jul 09 ’25, was worth 19,998. In this transaction Chief Medical Officer of this company sold 1,160 shares at a rate of $17.24, taking the stock ownership to the 224,210 shares. Before that another transaction happened on Jul 09 ’25, when Company’s Chief Technology Officer sold 1,519 for $17.24, making the entire transaction worth $26,188. This insider now owns 207,724 shares in total.
Immunovant Inc (IMVT) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -4.63% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.56% during the next five years compared to -12.18% drop over the previous five years of trading.
Immunovant Inc (NASDAQ: IMVT) Trading Performance Indicators
Check out the current performance indicators for Immunovant Inc (IMVT). In the past quarter, the stock posted a quick ratio of 11.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.74, a number that is poised to hit -0.69 in the next quarter and is forecasted to reach -2.85 in one year’s time.
Technical Analysis of Immunovant Inc (IMVT)
Immunovant Inc (NASDAQ: IMVT) saw its 5-day average volume 1.19 million, a negative change from its year-to-date volume of 1.5 million. As of the previous 9 days, the stock’s Stochastic %D was 92.46%.
During the past 100 days, Immunovant Inc’s (IMVT) raw stochastic average was set at 60.51%, which indicates a significant decrease from 96.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.72 in the past 14 days, which was lower than the 0.96 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.50, while its 200-day Moving Average is $21.57. Nevertheless, the first resistance level for the watch stands at $18.55 in the near term. At $18.97, the stock is likely to face the second major resistance level. The third major resistance level sits at $19.71. If the price goes on to break the first support level at $17.39, it is likely to go to the next support level at $16.65. The third support level lies at $16.23 if the price breaches the second support level.
Immunovant Inc (NASDAQ: IMVT) Key Stats
There are currently 171,069K shares outstanding in the company with a market cap of 3.10 billion. Presently, the company’s annual sales total 0 K according to its annual income of -413,840 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -106,450 K.
